Global RNAi for Therapeutic Market Size, Status and Forecast 2020-2026
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
RNAi for Therapeutic is in the development stage and there is no use in the market. The fastest research is Clinical phrase III, Such as QP1-1007, QO1-1002 of Quark Pharmaceuticals. The major technology of RNAi for Therapeutic is siRNA, miRNA and shRNA. SiRNA technology is the most popular, with the expenses market share of 85%, following SiRNA, miRNA is the second of 16% expenses market share in 2015.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the RNAi for Therapeutic market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the RNAi for Therapeutic industry.
Based on our recent survey, we have several different scenarios about the RNAi for Therapeutic YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ 1521.7 million in 2019. The market size of RNAi for Therapeutic will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global RNAi for Therapeutic market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global RNAi for Therapeutic market in terms of revenue.
Players, stakeholders, and other participants in the global RNAi for Therapeutic market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global RNAi for Therapeutic market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global RNAi for Therapeutic market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global RNAi for Therapeutic market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global RNAi for Therapeutic market.
The following players are covered in this report:
RNAi for Therapeutic is in the development stage and there is no use in the market. The fastest research is Clinical phrase III, Such as QP1-1007, QO1-1002 of Quark Pharmaceuticals. The major technology of RNAi for Therapeutic is siRNA, miRNA and shRNA. SiRNA technology is the most popular, with the expenses market share of 85%, following SiRNA, miRNA is the second of 16% expenses market share in 2015.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the RNAi for Therapeutic market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the RNAi for Therapeutic industry.
Based on our recent survey, we have several different scenarios about the RNAi for Therapeutic YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ 1521.7 million in 2019. The market size of RNAi for Therapeutic will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global RNAi for Therapeutic market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global RNAi for Therapeutic market in terms of revenue.
Players, stakeholders, and other participants in the global RNAi for Therapeutic market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global RNAi for Therapeutic market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global RNAi for Therapeutic market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global RNAi for Therapeutic market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global RNAi for Therapeutic market.
The following players are covered in this report:
- Alnylam Pharmaceuticals
- Arbutus Biopharma (Tekmira)
- Arrowhead
- Dicerna Pharmaceuticals
- Mirna Therapeutics
- Quark Pharmaceuticals
- RXi Pharmaceuticals
- Silence Therapeutics
- Benitec Biopharma
- miRagen Therapeutics
- Sylentis
- Gradalis
- Sirnaomics
- Silenseed
- siRNA
- miRNA
- shRNA
- Cancer
- Cardiovascular
- HBV
- Other
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by RNAi for Therapeutic Revenue
1.4 Market Analysis by Type
1.4.1 Global RNAi for Therapeutic Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 siRNA
1.4.3 miRNA
1.4.4 shRNA
1.5 Market by Application
1.5.1 Global RNAi for Therapeutic Market Share by Application: 2020 VS 2026
1.5.2 Cancer
1.5.3 Cardiovascular
1.5.4 HBV
1.5.5 Other
1.6 Coronavirus Disease 2019 (Covid-19): RNAi for Therapeutic Industry Impact
1.6.1 How the Covid-19 is Affecting the RNAi for Therapeutic Industry
1.6.1.1 RNAi for Therapeutic Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and RNAi for Therapeutic Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for RNAi for Therapeutic Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 RNAi for Therapeutic Market Perspective (2015-2026)
2.2 RNAi for Therapeutic Growth Trends by Regions
2.2.1 RNAi for Therapeutic Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 RNAi for Therapeutic Historic Market Share by Regions (2015-2020)
2.2.3 RNAi for Therapeutic Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 RNAi for Therapeutic Market Growth Strategy
2.3.6 Primary Interviews with Key RNAi for Therapeutic Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top RNAi for Therapeutic Players by Market Size
3.1.1 Global Top RNAi for Therapeutic Players by Revenue (2015-2020)
3.1.2 Global RNAi for Therapeutic Revenue Market Share by Players (2015-2020)
3.1.3 Global RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global RNAi for Therapeutic Market Concentration Ratio
3.2.1 Global RNAi for Therapeutic Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by RNAi for Therapeutic Revenue in 2019
3.3 RNAi for Therapeutic Key Players Head office and Area Served
3.4 Key Players RNAi for Therapeutic Product Solution and Service
3.5 Date of Enter into RNAi for Therapeutic Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global RNAi for Therapeutic Historic Market Size by Type (2015-2020)
4.2 Global RNAi for Therapeutic Forecasted Market Size by Type (2021-2026)
5 RNAI FOR THERAPEUTIC BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global RNAi for Therapeutic Market Size by Application (2015-2020)
5.2 Global RNAi for Therapeutic Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America RNAi for Therapeutic Market Size (2015-2020)
6.2 RNAi for Therapeutic Key Players in North America (2019-2020)
6.3 North America RNAi for Therapeutic Market Size by Type (2015-2020)
6.4 North America RNAi for Therapeutic Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe RNAi for Therapeutic Market Size (2015-2020)
7.2 RNAi for Therapeutic Key Players in Europe (2019-2020)
7.3 Europe RNAi for Therapeutic Market Size by Type (2015-2020)
7.4 Europe RNAi for Therapeutic Market Size by Application (2015-2020)
8 CHINA
8.1 China RNAi for Therapeutic Market Size (2015-2020)
8.2 RNAi for Therapeutic Key Players in China (2019-2020)
8.3 China RNAi for Therapeutic Market Size by Type (2015-2020)
8.4 China RNAi for Therapeutic Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan RNAi for Therapeutic Market Size (2015-2020)
9.2 RNAi for Therapeutic Key Players in Japan (2019-2020)
9.3 Japan RNAi for Therapeutic Market Size by Type (2015-2020)
9.4 Japan RNAi for Therapeutic Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia RNAi for Therapeutic Market Size (2015-2020)
10.2 RNAi for Therapeutic Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia RNAi for Therapeutic Market Size by Type (2015-2020)
10.4 Southeast Asia RNAi for Therapeutic Market Size by Application (2015-2020)
11 INDIA
11.1 India RNAi for Therapeutic Market Size (2015-2020)
11.2 RNAi for Therapeutic Key Players in India (2019-2020)
11.3 India RNAi for Therapeutic Market Size by Type (2015-2020)
11.4 India RNAi for Therapeutic Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America RNAi for Therapeutic Market Size (2015-2020)
12.2 RNAi for Therapeutic Key Players in Central & South America (2019-2020)
12.3 Central & South America RNAi for Therapeutic Market Size by Type (2015-2020)
12.4 Central & South America RNAi for Therapeutic Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Alnylam Pharmaceuticals
13.1.1 Alnylam Pharmaceuticals Company Details
13.1.2 Alnylam Pharmaceuticals Business Overview and Its Total Revenue
13.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Introduction
13.1.4 Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2015-2020))
13.1.5 Alnylam Pharmaceuticals Recent Development
13.2 Arbutus Biopharma (Tekmira)
13.2.1 Arbutus Biopharma (Tekmira) Company Details
13.2.2 Arbutus Biopharma (Tekmira) Business Overview and Its Total Revenue
13.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Introduction
13.2.4 Arbutus Biopharma (Tekmira) Revenue in RNAi for Therapeutic Business (2015-2020)
13.2.5 Arbutus Biopharma (Tekmira) Recent Development
13.3 Arrowhead
13.3.1 Arrowhead Company Details
13.3.2 Arrowhead Business Overview and Its Total Revenue
13.3.3 Arrowhead RNAi for Therapeutic Introduction
13.3.4 Arrowhead Revenue in RNAi for Therapeutic Business (2015-2020)
13.3.5 Arrowhead Recent Development
13.4 Dicerna Pharmaceuticals
13.4.1 Dicerna Pharmaceuticals Company Details
13.4.2 Dicerna Pharmaceuticals Business Overview and Its Total Revenue
13.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Introduction
13.4.4 Dicerna Pharmaceuticals Revenue in RNAi for Therapeutic Business (2015-2020)
13.4.5 Dicerna Pharmaceuticals Recent Development
13.5 Mirna Therapeutics
13.5.1 Mirna Therapeutics Company Details
13.5.2 Mirna Therapeutics Business Overview and Its Total Revenue
13.5.3 Mirna Therapeutics RNAi for Therapeutic Introduction
13.5.4 Mirna Therapeutics Revenue in RNAi for Therapeutic Business (2015-2020)
13.5.5 Mirna Therapeutics Recent Development
13.6 Quark Pharmaceuticals
13.6.1 Quark Pharmaceuticals Company Details
13.6.2 Quark Pharmaceuticals Business Overview and Its Total Revenue
13.6.3 Quark Pharmaceuticals RNAi for Therapeutic Introduction
13.6.4 Quark Pharmaceuticals Revenue in RNAi for Therapeutic Business (2015-2020)
13.6.5 Quark Pharmaceuticals Recent Development
13.7 RXi Pharmaceuticals
13.7.1 RXi Pharmaceuticals Company Details
13.7.2 RXi Pharmaceuticals Business Overview and Its Total Revenue
13.7.3 RXi Pharmaceuticals RNAi for Therapeutic Introduction
13.7.4 RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2015-2020)
13.7.5 RXi Pharmaceuticals Recent Development
13.8 Silence Therapeutics
13.8.1 Silence Therapeutics Company Details
13.8.2 Silence Therapeutics Business Overview and Its Total Revenue
13.8.3 Silence Therapeutics RNAi for Therapeutic Introduction
13.8.4 Silence Therapeutics Revenue in RNAi for Therapeutic Business (2015-2020)
13.8.5 Silence Therapeutics Recent Development
13.9 Benitec Biopharma
13.9.1 Benitec Biopharma Company Details
13.9.2 Benitec Biopharma Business Overview and Its Total Revenue
13.9.3 Benitec Biopharma RNAi for Therapeutic Introduction
13.9.4 Benitec Biopharma Revenue in RNAi for Therapeutic Business (2015-2020)
13.9.5 Benitec Biopharma Recent Development
13.10 miRagen Therapeutics
13.10.1 miRagen Therapeutics Company Details
13.10.2 miRagen Therapeutics Business Overview and Its Total Revenue
13.10.3 miRagen Therapeutics RNAi for Therapeutic Introduction
13.10.4 miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2015-2020)
13.10.5 miRagen Therapeutics Recent Development
13.11 Sylentis
10.11.1 Sylentis Company Details
10.11.2 Sylentis Business Overview and Its Total Revenue
10.11.3 Sylentis RNAi for Therapeutic Introduction
10.11.4 Sylentis Revenue in RNAi for Therapeutic Business (2015-2020)
10.11.5 Sylentis Recent Development
13.12 Gradalis
10.12.1 Gradalis Company Details
10.12.2 Gradalis Business Overview and Its Total Revenue
10.12.3 Gradalis RNAi for Therapeutic Introduction
10.12.4 Gradalis Revenue in RNAi for Therapeutic Business (2015-2020)
10.12.5 Gradalis Recent Development
13.13 Sirnaomics
10.13.1 Sirnaomics Company Details
10.13.2 Sirnaomics Business Overview and Its Total Revenue
10.13.3 Sirnaomics RNAi for Therapeutic Introduction
10.13.4 Sirnaomics Revenue in RNAi for Therapeutic Business (2015-2020)
10.13.5 Sirnaomics Recent Development
13.14 Silenseed
10.14.1 Silenseed Company Details
10.14.2 Silenseed Business Overview and Its Total Revenue
10.14.3 Silenseed RNAi for Therapeutic Introduction
10.14.4 Silenseed Revenue in RNAi for Therapeutic Business (2015-2020)
10.14.5 Silenseed Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by RNAi for Therapeutic Revenue
1.4 Market Analysis by Type
1.4.1 Global RNAi for Therapeutic Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 siRNA
1.4.3 miRNA
1.4.4 shRNA
1.5 Market by Application
1.5.1 Global RNAi for Therapeutic Market Share by Application: 2020 VS 2026
1.5.2 Cancer
1.5.3 Cardiovascular
1.5.4 HBV
1.5.5 Other
1.6 Coronavirus Disease 2019 (Covid-19): RNAi for Therapeutic Industry Impact
1.6.1 How the Covid-19 is Affecting the RNAi for Therapeutic Industry
1.6.1.1 RNAi for Therapeutic Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and RNAi for Therapeutic Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for RNAi for Therapeutic Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 RNAi for Therapeutic Market Perspective (2015-2026)
2.2 RNAi for Therapeutic Growth Trends by Regions
2.2.1 RNAi for Therapeutic Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 RNAi for Therapeutic Historic Market Share by Regions (2015-2020)
2.2.3 RNAi for Therapeutic Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 RNAi for Therapeutic Market Growth Strategy
2.3.6 Primary Interviews with Key RNAi for Therapeutic Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top RNAi for Therapeutic Players by Market Size
3.1.1 Global Top RNAi for Therapeutic Players by Revenue (2015-2020)
3.1.2 Global RNAi for Therapeutic Revenue Market Share by Players (2015-2020)
3.1.3 Global RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global RNAi for Therapeutic Market Concentration Ratio
3.2.1 Global RNAi for Therapeutic Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by RNAi for Therapeutic Revenue in 2019
3.3 RNAi for Therapeutic Key Players Head office and Area Served
3.4 Key Players RNAi for Therapeutic Product Solution and Service
3.5 Date of Enter into RNAi for Therapeutic Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global RNAi for Therapeutic Historic Market Size by Type (2015-2020)
4.2 Global RNAi for Therapeutic Forecasted Market Size by Type (2021-2026)
5 RNAI FOR THERAPEUTIC BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global RNAi for Therapeutic Market Size by Application (2015-2020)
5.2 Global RNAi for Therapeutic Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America RNAi for Therapeutic Market Size (2015-2020)
6.2 RNAi for Therapeutic Key Players in North America (2019-2020)
6.3 North America RNAi for Therapeutic Market Size by Type (2015-2020)
6.4 North America RNAi for Therapeutic Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe RNAi for Therapeutic Market Size (2015-2020)
7.2 RNAi for Therapeutic Key Players in Europe (2019-2020)
7.3 Europe RNAi for Therapeutic Market Size by Type (2015-2020)
7.4 Europe RNAi for Therapeutic Market Size by Application (2015-2020)
8 CHINA
8.1 China RNAi for Therapeutic Market Size (2015-2020)
8.2 RNAi for Therapeutic Key Players in China (2019-2020)
8.3 China RNAi for Therapeutic Market Size by Type (2015-2020)
8.4 China RNAi for Therapeutic Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan RNAi for Therapeutic Market Size (2015-2020)
9.2 RNAi for Therapeutic Key Players in Japan (2019-2020)
9.3 Japan RNAi for Therapeutic Market Size by Type (2015-2020)
9.4 Japan RNAi for Therapeutic Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia RNAi for Therapeutic Market Size (2015-2020)
10.2 RNAi for Therapeutic Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia RNAi for Therapeutic Market Size by Type (2015-2020)
10.4 Southeast Asia RNAi for Therapeutic Market Size by Application (2015-2020)
11 INDIA
11.1 India RNAi for Therapeutic Market Size (2015-2020)
11.2 RNAi for Therapeutic Key Players in India (2019-2020)
11.3 India RNAi for Therapeutic Market Size by Type (2015-2020)
11.4 India RNAi for Therapeutic Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America RNAi for Therapeutic Market Size (2015-2020)
12.2 RNAi for Therapeutic Key Players in Central & South America (2019-2020)
12.3 Central & South America RNAi for Therapeutic Market Size by Type (2015-2020)
12.4 Central & South America RNAi for Therapeutic Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Alnylam Pharmaceuticals
13.1.1 Alnylam Pharmaceuticals Company Details
13.1.2 Alnylam Pharmaceuticals Business Overview and Its Total Revenue
13.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Introduction
13.1.4 Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2015-2020))
13.1.5 Alnylam Pharmaceuticals Recent Development
13.2 Arbutus Biopharma (Tekmira)
13.2.1 Arbutus Biopharma (Tekmira) Company Details
13.2.2 Arbutus Biopharma (Tekmira) Business Overview and Its Total Revenue
13.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Introduction
13.2.4 Arbutus Biopharma (Tekmira) Revenue in RNAi for Therapeutic Business (2015-2020)
13.2.5 Arbutus Biopharma (Tekmira) Recent Development
13.3 Arrowhead
13.3.1 Arrowhead Company Details
13.3.2 Arrowhead Business Overview and Its Total Revenue
13.3.3 Arrowhead RNAi for Therapeutic Introduction
13.3.4 Arrowhead Revenue in RNAi for Therapeutic Business (2015-2020)
13.3.5 Arrowhead Recent Development
13.4 Dicerna Pharmaceuticals
13.4.1 Dicerna Pharmaceuticals Company Details
13.4.2 Dicerna Pharmaceuticals Business Overview and Its Total Revenue
13.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Introduction
13.4.4 Dicerna Pharmaceuticals Revenue in RNAi for Therapeutic Business (2015-2020)
13.4.5 Dicerna Pharmaceuticals Recent Development
13.5 Mirna Therapeutics
13.5.1 Mirna Therapeutics Company Details
13.5.2 Mirna Therapeutics Business Overview and Its Total Revenue
13.5.3 Mirna Therapeutics RNAi for Therapeutic Introduction
13.5.4 Mirna Therapeutics Revenue in RNAi for Therapeutic Business (2015-2020)
13.5.5 Mirna Therapeutics Recent Development
13.6 Quark Pharmaceuticals
13.6.1 Quark Pharmaceuticals Company Details
13.6.2 Quark Pharmaceuticals Business Overview and Its Total Revenue
13.6.3 Quark Pharmaceuticals RNAi for Therapeutic Introduction
13.6.4 Quark Pharmaceuticals Revenue in RNAi for Therapeutic Business (2015-2020)
13.6.5 Quark Pharmaceuticals Recent Development
13.7 RXi Pharmaceuticals
13.7.1 RXi Pharmaceuticals Company Details
13.7.2 RXi Pharmaceuticals Business Overview and Its Total Revenue
13.7.3 RXi Pharmaceuticals RNAi for Therapeutic Introduction
13.7.4 RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2015-2020)
13.7.5 RXi Pharmaceuticals Recent Development
13.8 Silence Therapeutics
13.8.1 Silence Therapeutics Company Details
13.8.2 Silence Therapeutics Business Overview and Its Total Revenue
13.8.3 Silence Therapeutics RNAi for Therapeutic Introduction
13.8.4 Silence Therapeutics Revenue in RNAi for Therapeutic Business (2015-2020)
13.8.5 Silence Therapeutics Recent Development
13.9 Benitec Biopharma
13.9.1 Benitec Biopharma Company Details
13.9.2 Benitec Biopharma Business Overview and Its Total Revenue
13.9.3 Benitec Biopharma RNAi for Therapeutic Introduction
13.9.4 Benitec Biopharma Revenue in RNAi for Therapeutic Business (2015-2020)
13.9.5 Benitec Biopharma Recent Development
13.10 miRagen Therapeutics
13.10.1 miRagen Therapeutics Company Details
13.10.2 miRagen Therapeutics Business Overview and Its Total Revenue
13.10.3 miRagen Therapeutics RNAi for Therapeutic Introduction
13.10.4 miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2015-2020)
13.10.5 miRagen Therapeutics Recent Development
13.11 Sylentis
10.11.1 Sylentis Company Details
10.11.2 Sylentis Business Overview and Its Total Revenue
10.11.3 Sylentis RNAi for Therapeutic Introduction
10.11.4 Sylentis Revenue in RNAi for Therapeutic Business (2015-2020)
10.11.5 Sylentis Recent Development
13.12 Gradalis
10.12.1 Gradalis Company Details
10.12.2 Gradalis Business Overview and Its Total Revenue
10.12.3 Gradalis RNAi for Therapeutic Introduction
10.12.4 Gradalis Revenue in RNAi for Therapeutic Business (2015-2020)
10.12.5 Gradalis Recent Development
13.13 Sirnaomics
10.13.1 Sirnaomics Company Details
10.13.2 Sirnaomics Business Overview and Its Total Revenue
10.13.3 Sirnaomics RNAi for Therapeutic Introduction
10.13.4 Sirnaomics Revenue in RNAi for Therapeutic Business (2015-2020)
10.13.5 Sirnaomics Recent Development
13.14 Silenseed
10.14.1 Silenseed Company Details
10.14.2 Silenseed Business Overview and Its Total Revenue
10.14.3 Silenseed RNAi for Therapeutic Introduction
10.14.4 Silenseed Revenue in RNAi for Therapeutic Business (2015-2020)
10.14.5 Silenseed Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
LIST OF TABLES
Table 1. RNAi for Therapeutic Key Market Segments
Table 2. Key Players Covered: Ranking by RNAi for Therapeutic Revenue
Table 3. Ranking of Global Top RNAi for Therapeutic Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global RNAi for Therapeutic Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of siRNA
Table 6. Key Players of miRNA
Table 7. Key Players of shRNA
Table 8. COVID-19 Impact Global Market: (Four RNAi for Therapeutic Market Size Forecast Scenarios)
Table 9. Opportunities and Trends for RNAi for Therapeutic Players in the COVID-19 Landscape
Table 10. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 11. Key Regions/Countries Measures against Covid-19 Impact
Table 12. Proposal for RNAi for Therapeutic Players to Combat Covid-19 Impact
Table 13. Global RNAi for Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 14. Global RNAi for Therapeutic Market Size by Regions (US$ Million): 2020 VS 2026
Table 15. Global RNAi for Therapeutic Market Size by Regions (2015-2020) (US$ Million)
Table 16. Global RNAi for Therapeutic Market Share by Regions (2015-2020)
Table 17. Global RNAi for Therapeutic Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 18. Global RNAi for Therapeutic Market Share by Regions (2021-2026)
Table 19. Market Top Trends
Table 20. Key Drivers: Impact Analysis
Table 21. Key Challenges
Table 22. RNAi for Therapeutic Market Growth Strategy
Table 23. Main Points Interviewed from Key RNAi for Therapeutic Players
Table 24. Global RNAi for Therapeutic Revenue by Players (2015-2020) (Million US$)
Table 25. Global RNAi for Therapeutic Market Share by Players (2015-2020)
Table 26. Global Top RNAi for Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in RNAi for Therapeutic as of 2019)
Table 27. Global RNAi for Therapeutic by Players Market Concentration Ratio (CR5 and HHI)
Table 28. Key Players Headquarters and Area Served
Table 29. Key Players RNAi for Therapeutic Product Solution and Service
Table 30. Date of Enter into RNAi for Therapeutic Market
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global RNAi for Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 33. Global RNAi for Therapeutic Market Size Share by Type (2015-2020)
Table 34. Global RNAi for Therapeutic Revenue Market Share by Type (2021-2026)
Table 35. Global RNAi for Therapeutic Market Size Share by Application (2015-2020)
Table 36. Global RNAi for Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 37. Global RNAi for Therapeutic Market Size Share by Application (2021-2026)
Table 38. North America Key Players RNAi for Therapeutic Revenue (2019-2020) (Million US$)
Table 39. North America Key Players RNAi for Therapeutic Market Share (2019-2020)
Table 40. North America RNAi for Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 41. North America RNAi for Therapeutic Market Share by Type (2015-2020)
Table 42. North America RNAi for Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 43. North America RNAi for Therapeutic Market Share by Application (2015-2020)
Table 44. Europe Key Players RNAi for Therapeutic Revenue (2019-2020) (Million US$)
Table 45. Europe Key Players RNAi for Therapeutic Market Share (2019-2020)
Table 46. Europe RNAi for Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 47. Europe RNAi for Therapeutic Market Share by Type (2015-2020)
Table 48. Europe RNAi for Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 49. Europe RNAi for Therapeutic Market Share by Application (2015-2020)
Table 50. China Key Players RNAi for Therapeutic Revenue (2019-2020) (Million US$)
Table 51. China Key Players RNAi for Therapeutic Market Share (2019-2020)
Table 52. China RNAi for Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 53. China RNAi for Therapeutic Market Share by Type (2015-2020)
Table 54. China RNAi for Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 55. China RNAi for Therapeutic Market Share by Application (2015-2020)
Table 56. Japan Key Players RNAi for Therapeutic Revenue (2019-2020) (Million US$)
Table 57. Japan Key Players RNAi for Therapeutic Market Share (2019-2020)
Table 58. Japan RNAi for Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 59. Japan RNAi for Therapeutic Market Share by Type (2015-2020)
Table 60. Japan RNAi for Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 61. Japan RNAi for Therapeutic Market Share by Application (2015-2020)
Table 62. Southeast Asia Key Players RNAi for Therapeutic Revenue (2019-2020) (Million US$)
Table 63. Southeast Asia Key Players RNAi for Therapeutic Market Share (2019-2020)
Table 64. Southeast Asia RNAi for Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 65. Southeast Asia RNAi for Therapeutic Market Share by Type (2015-2020)
Table 66. Southeast Asia RNAi for Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 67. Southeast Asia RNAi for Therapeutic Market Share by Application (2015-2020)
Table 68. India Key Players RNAi for Therapeutic Revenue (2019-2020) (Million US$)
Table 69. India Key Players RNAi for Therapeutic Market Share (2019-2020)
Table 70. India RNAi for Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 71. India RNAi for Therapeutic Market Share by Type (2015-2020)
Table 72. India RNAi for Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 73. India RNAi for Therapeutic Market Share by Application (2015-2020)
Table 74. Central & South America Key Players RNAi for Therapeutic Revenue (2019-2020) (Million US$)
Table 75. Central & South America Key Players RNAi for Therapeutic Market Share (2019-2020)
Table 76. Central & South America RNAi for Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 77. Central & South America RNAi for Therapeutic Market Share by Type (2015-2020)
Table 78. Central & South America RNAi for Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 79. Central & South America RNAi for Therapeutic Market Share by Application (2015-2020)
Table 80. Alnylam Pharmaceuticals Company Details
Table 81. Alnylam Pharmaceuticals Business Overview
Table 82. Alnylam Pharmaceuticals Product
Table 83. Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 84. Alnylam Pharmaceuticals Recent Development
Table 85. Arbutus Biopharma (Tekmira) Company Details
Table 86. Arbutus Biopharma (Tekmira) Business Overview
Table 87. Arbutus Biopharma (Tekmira) Product
Table 88. Arbutus Biopharma (Tekmira) Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 89. Arbutus Biopharma (Tekmira) Recent Development
Table 90. Arrowhead Company Details
Table 91. Arrowhead Business Overview
Table 92. Arrowhead Product
Table 93. Arrowhead Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 94. Arrowhead Recent Development
Table 95. Dicerna Pharmaceuticals Company Details
Table 96. Dicerna Pharmaceuticals Business Overview
Table 97. Dicerna Pharmaceuticals Product
Table 98. Dicerna Pharmaceuticals Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 99. Dicerna Pharmaceuticals Recent Development
Table 100. Mirna Therapeutics Company Details
Table 101. Mirna Therapeutics Business Overview
Table 102. Mirna Therapeutics Product
Table 103. Mirna Therapeutics Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 104. Mirna Therapeutics Recent Development
Table 105. Quark Pharmaceuticals Company Details
Table 106. Quark Pharmaceuticals Business Overview
Table 107. Quark Pharmaceuticals Product
Table 108. Quark Pharmaceuticals Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 109. Quark Pharmaceuticals Recent Development
Table 110. RXi Pharmaceuticals Company Details
Table 111. RXi Pharmaceuticals Business Overview
Table 112. RXi Pharmaceuticals Product
Table 113. RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 114. RXi Pharmaceuticals Recent Development
Table 115. Silence Therapeutics Business Overview
Table 116. Silence Therapeutics Product
Table 117. Silence Therapeutics Company Details
Table 118. Silence Therapeutics Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 119. Silence Therapeutics Recent Development
Table 120. Benitec Biopharma Company Details
Table 121. Benitec Biopharma Business Overview
Table 122. Benitec Biopharma Product
Table 123. Benitec Biopharma Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 124. Benitec Biopharma Recent Development
Table 125. miRagen Therapeutics Company Details
Table 126. miRagen Therapeutics Business Overview
Table 127. miRagen Therapeutics Product
Table 128. miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 129. miRagen Therapeutics Recent Development
Table 130. Sylentis Company Details
Table 131. Sylentis Business Overview
Table 132. Sylentis Product
Table 133. Sylentis Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 134. Sylentis Recent Development
Table 135. Gradalis Company Details
Table 136. Gradalis Business Overview
Table 137. Gradalis Product
Table 138. Gradalis Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 139. Gradalis Recent Development
Table 140. Sirnaomics Company Details
Table 141. Sirnaomics Business Overview
Table 142. Sirnaomics Product
Table 143. Sirnaomics Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 144. Sirnaomics Recent Development
Table 145. Silenseed Company Details
Table 146. Silenseed Business Overview
Table 147. Silenseed Product
Table 148. Silenseed Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 149. Silenseed Recent Development
Table 150. Research Programs/Design for This Report
Table 151. Key Data Information from Secondary Sources
Table 152. Key Data Information from Primary Sources
Table 1. RNAi for Therapeutic Key Market Segments
Table 2. Key Players Covered: Ranking by RNAi for Therapeutic Revenue
Table 3. Ranking of Global Top RNAi for Therapeutic Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global RNAi for Therapeutic Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of siRNA
Table 6. Key Players of miRNA
Table 7. Key Players of shRNA
Table 8. COVID-19 Impact Global Market: (Four RNAi for Therapeutic Market Size Forecast Scenarios)
Table 9. Opportunities and Trends for RNAi for Therapeutic Players in the COVID-19 Landscape
Table 10. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 11. Key Regions/Countries Measures against Covid-19 Impact
Table 12. Proposal for RNAi for Therapeutic Players to Combat Covid-19 Impact
Table 13. Global RNAi for Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 14. Global RNAi for Therapeutic Market Size by Regions (US$ Million): 2020 VS 2026
Table 15. Global RNAi for Therapeutic Market Size by Regions (2015-2020) (US$ Million)
Table 16. Global RNAi for Therapeutic Market Share by Regions (2015-2020)
Table 17. Global RNAi for Therapeutic Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 18. Global RNAi for Therapeutic Market Share by Regions (2021-2026)
Table 19. Market Top Trends
Table 20. Key Drivers: Impact Analysis
Table 21. Key Challenges
Table 22. RNAi for Therapeutic Market Growth Strategy
Table 23. Main Points Interviewed from Key RNAi for Therapeutic Players
Table 24. Global RNAi for Therapeutic Revenue by Players (2015-2020) (Million US$)
Table 25. Global RNAi for Therapeutic Market Share by Players (2015-2020)
Table 26. Global Top RNAi for Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in RNAi for Therapeutic as of 2019)
Table 27. Global RNAi for Therapeutic by Players Market Concentration Ratio (CR5 and HHI)
Table 28. Key Players Headquarters and Area Served
Table 29. Key Players RNAi for Therapeutic Product Solution and Service
Table 30. Date of Enter into RNAi for Therapeutic Market
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global RNAi for Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 33. Global RNAi for Therapeutic Market Size Share by Type (2015-2020)
Table 34. Global RNAi for Therapeutic Revenue Market Share by Type (2021-2026)
Table 35. Global RNAi for Therapeutic Market Size Share by Application (2015-2020)
Table 36. Global RNAi for Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 37. Global RNAi for Therapeutic Market Size Share by Application (2021-2026)
Table 38. North America Key Players RNAi for Therapeutic Revenue (2019-2020) (Million US$)
Table 39. North America Key Players RNAi for Therapeutic Market Share (2019-2020)
Table 40. North America RNAi for Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 41. North America RNAi for Therapeutic Market Share by Type (2015-2020)
Table 42. North America RNAi for Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 43. North America RNAi for Therapeutic Market Share by Application (2015-2020)
Table 44. Europe Key Players RNAi for Therapeutic Revenue (2019-2020) (Million US$)
Table 45. Europe Key Players RNAi for Therapeutic Market Share (2019-2020)
Table 46. Europe RNAi for Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 47. Europe RNAi for Therapeutic Market Share by Type (2015-2020)
Table 48. Europe RNAi for Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 49. Europe RNAi for Therapeutic Market Share by Application (2015-2020)
Table 50. China Key Players RNAi for Therapeutic Revenue (2019-2020) (Million US$)
Table 51. China Key Players RNAi for Therapeutic Market Share (2019-2020)
Table 52. China RNAi for Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 53. China RNAi for Therapeutic Market Share by Type (2015-2020)
Table 54. China RNAi for Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 55. China RNAi for Therapeutic Market Share by Application (2015-2020)
Table 56. Japan Key Players RNAi for Therapeutic Revenue (2019-2020) (Million US$)
Table 57. Japan Key Players RNAi for Therapeutic Market Share (2019-2020)
Table 58. Japan RNAi for Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 59. Japan RNAi for Therapeutic Market Share by Type (2015-2020)
Table 60. Japan RNAi for Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 61. Japan RNAi for Therapeutic Market Share by Application (2015-2020)
Table 62. Southeast Asia Key Players RNAi for Therapeutic Revenue (2019-2020) (Million US$)
Table 63. Southeast Asia Key Players RNAi for Therapeutic Market Share (2019-2020)
Table 64. Southeast Asia RNAi for Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 65. Southeast Asia RNAi for Therapeutic Market Share by Type (2015-2020)
Table 66. Southeast Asia RNAi for Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 67. Southeast Asia RNAi for Therapeutic Market Share by Application (2015-2020)
Table 68. India Key Players RNAi for Therapeutic Revenue (2019-2020) (Million US$)
Table 69. India Key Players RNAi for Therapeutic Market Share (2019-2020)
Table 70. India RNAi for Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 71. India RNAi for Therapeutic Market Share by Type (2015-2020)
Table 72. India RNAi for Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 73. India RNAi for Therapeutic Market Share by Application (2015-2020)
Table 74. Central & South America Key Players RNAi for Therapeutic Revenue (2019-2020) (Million US$)
Table 75. Central & South America Key Players RNAi for Therapeutic Market Share (2019-2020)
Table 76. Central & South America RNAi for Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 77. Central & South America RNAi for Therapeutic Market Share by Type (2015-2020)
Table 78. Central & South America RNAi for Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 79. Central & South America RNAi for Therapeutic Market Share by Application (2015-2020)
Table 80. Alnylam Pharmaceuticals Company Details
Table 81. Alnylam Pharmaceuticals Business Overview
Table 82. Alnylam Pharmaceuticals Product
Table 83. Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 84. Alnylam Pharmaceuticals Recent Development
Table 85. Arbutus Biopharma (Tekmira) Company Details
Table 86. Arbutus Biopharma (Tekmira) Business Overview
Table 87. Arbutus Biopharma (Tekmira) Product
Table 88. Arbutus Biopharma (Tekmira) Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 89. Arbutus Biopharma (Tekmira) Recent Development
Table 90. Arrowhead Company Details
Table 91. Arrowhead Business Overview
Table 92. Arrowhead Product
Table 93. Arrowhead Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 94. Arrowhead Recent Development
Table 95. Dicerna Pharmaceuticals Company Details
Table 96. Dicerna Pharmaceuticals Business Overview
Table 97. Dicerna Pharmaceuticals Product
Table 98. Dicerna Pharmaceuticals Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 99. Dicerna Pharmaceuticals Recent Development
Table 100. Mirna Therapeutics Company Details
Table 101. Mirna Therapeutics Business Overview
Table 102. Mirna Therapeutics Product
Table 103. Mirna Therapeutics Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 104. Mirna Therapeutics Recent Development
Table 105. Quark Pharmaceuticals Company Details
Table 106. Quark Pharmaceuticals Business Overview
Table 107. Quark Pharmaceuticals Product
Table 108. Quark Pharmaceuticals Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 109. Quark Pharmaceuticals Recent Development
Table 110. RXi Pharmaceuticals Company Details
Table 111. RXi Pharmaceuticals Business Overview
Table 112. RXi Pharmaceuticals Product
Table 113. RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 114. RXi Pharmaceuticals Recent Development
Table 115. Silence Therapeutics Business Overview
Table 116. Silence Therapeutics Product
Table 117. Silence Therapeutics Company Details
Table 118. Silence Therapeutics Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 119. Silence Therapeutics Recent Development
Table 120. Benitec Biopharma Company Details
Table 121. Benitec Biopharma Business Overview
Table 122. Benitec Biopharma Product
Table 123. Benitec Biopharma Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 124. Benitec Biopharma Recent Development
Table 125. miRagen Therapeutics Company Details
Table 126. miRagen Therapeutics Business Overview
Table 127. miRagen Therapeutics Product
Table 128. miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 129. miRagen Therapeutics Recent Development
Table 130. Sylentis Company Details
Table 131. Sylentis Business Overview
Table 132. Sylentis Product
Table 133. Sylentis Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 134. Sylentis Recent Development
Table 135. Gradalis Company Details
Table 136. Gradalis Business Overview
Table 137. Gradalis Product
Table 138. Gradalis Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 139. Gradalis Recent Development
Table 140. Sirnaomics Company Details
Table 141. Sirnaomics Business Overview
Table 142. Sirnaomics Product
Table 143. Sirnaomics Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 144. Sirnaomics Recent Development
Table 145. Silenseed Company Details
Table 146. Silenseed Business Overview
Table 147. Silenseed Product
Table 148. Silenseed Revenue in RNAi for Therapeutic Business (2015-2020) (Million US$)
Table 149. Silenseed Recent Development
Table 150. Research Programs/Design for This Report
Table 151. Key Data Information from Secondary Sources
Table 152. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global RNAi for Therapeutic Market Share by Type: 2020 VS 2026
Figure 2. siRNA Features
Figure 3. miRNA Features
Figure 4. shRNA Features
Figure 5. Global RNAi for Therapeutic Market Share by Application: 2020 VS 2026
Figure 6. Cancer Case Studies
Figure 7. Cardiovascular Case Studies
Figure 8. HBV Case Studies
Figure 9. Other Case Studies
Figure 10. RNAi for Therapeutic Report Years Considered
Figure 11. Global RNAi for Therapeutic Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global RNAi for Therapeutic Market Share by Regions: 2020 VS 2026
Figure 13. Global RNAi for Therapeutic Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global RNAi for Therapeutic Market Share by Players in 2019
Figure 16. Global Top RNAi for Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in RNAi for Therapeutic as of 2019
Figure 17. The Top 10 and 5 Players Market Share by RNAi for Therapeutic Revenue in 2019
Figure 18. North America RNAi for Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe RNAi for Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China RNAi for Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan RNAi for Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia RNAi for Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India RNAi for Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America RNAi for Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Alnylam Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Alnylam Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 27. Arbutus Biopharma (Tekmira) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Arbutus Biopharma (Tekmira) Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 29. Arrowhead Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Arrowhead Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 31. Dicerna Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Dicerna Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 33. Mirna Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Mirna Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 35. Quark Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Quark Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 37. RXi Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. RXi Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 39. Silence Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Silence Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 41. Benitec Biopharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Benitec Biopharma Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 43. miRagen Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. miRagen Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 45. Sylentis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Sylentis Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 47. Gradalis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Gradalis Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 49. Sirnaomics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Sirnaomics Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 51. Silenseed Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Silenseed Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
Figure 1. Global RNAi for Therapeutic Market Share by Type: 2020 VS 2026
Figure 2. siRNA Features
Figure 3. miRNA Features
Figure 4. shRNA Features
Figure 5. Global RNAi for Therapeutic Market Share by Application: 2020 VS 2026
Figure 6. Cancer Case Studies
Figure 7. Cardiovascular Case Studies
Figure 8. HBV Case Studies
Figure 9. Other Case Studies
Figure 10. RNAi for Therapeutic Report Years Considered
Figure 11. Global RNAi for Therapeutic Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global RNAi for Therapeutic Market Share by Regions: 2020 VS 2026
Figure 13. Global RNAi for Therapeutic Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global RNAi for Therapeutic Market Share by Players in 2019
Figure 16. Global Top RNAi for Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in RNAi for Therapeutic as of 2019
Figure 17. The Top 10 and 5 Players Market Share by RNAi for Therapeutic Revenue in 2019
Figure 18. North America RNAi for Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe RNAi for Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China RNAi for Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan RNAi for Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia RNAi for Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India RNAi for Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America RNAi for Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Alnylam Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Alnylam Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 27. Arbutus Biopharma (Tekmira) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Arbutus Biopharma (Tekmira) Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 29. Arrowhead Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Arrowhead Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 31. Dicerna Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Dicerna Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 33. Mirna Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Mirna Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 35. Quark Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Quark Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 37. RXi Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. RXi Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 39. Silence Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Silence Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 41. Benitec Biopharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Benitec Biopharma Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 43. miRagen Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. miRagen Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 45. Sylentis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Sylentis Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 47. Gradalis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Gradalis Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 49. Sirnaomics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Sirnaomics Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 51. Silenseed Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Silenseed Revenue Growth Rate in RNAi for Therapeutic Business (2015-2020)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
